Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-07-07

Clinical Trial Update: A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update evaluating safety and efficacy of ruxolitinib in myelofibrosis using a prognostic-stratification approach.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Qilu Hospital of Shandong University | Conditions: Myelofibrosis | Phase 4 | Status: UNKNOWN